ORYL F1 is a high-throughput, low-compound, plate-based solubility and aggregation profiling instrument, powered by Ultrafast Light Scattering.
Traditional solubility and aggregation workflows are slow, compound-hungry, and often deliver answers too late in the pipeline to make a difference.
ORYL F1 delivers high-throughput, low-compound solubility and aggregation profiling powered by Ultrafast Light Scattering, enabling better decisions from discovery through formulation.
The ORYL F1 is the first plate-based instrument to combine second harmonic scattering (SHS) and linear light scattering (LLS) in a single, high-throughput platform. From early discovery screening to pre-formulation profiling, the ORYL F1 delivers robust and reliable measurements that match pharma R&D timelines.
From hit-list screening in early discovery to formulation window mapping in pre-formulation, ORYL F1 supports the workflows that matter.
Screen entire hit lists for solubility early in discovery. Identify problematic compounds before they advance, using minimal compound.
Detect nanometer-scale aggregation before visible turbidity. Early insight into aggregation behavior supports better candidate selection.
Map formulation windows, quantify safety margins, and identify failure boundaries early. Define robust formulation conditions with confidence.
ORYL F1 combines second harmonic scattering (SHS) and linear light scattering (LLS) into a single measurement platform, offering complementary readouts that reveal molecular-level insight into solubility and aggregation behavior.
Probes molecular-level organization and early-onset aggregation events invisible to conventional light scattering methods.
Complements SHS with established scattering measurements to characterize particle size and aggregation growth with high sensitivity.
Detect subtle changes at the nanometer scale — early onset of aggregation prior to turbidity — giving teams earlier and more actionable insight.
Profile hundreds of conditions in minutes using standard 384-well plates, matching the pace of modern pharma R&D timelines.
The ORYL F1 gave us insight into our compound library that we simply could not get with our existing tools. We identified solubility risks weeks earlier than before.
Discovery Scientist
What impressed us was the combination of throughput and low compound use. We profiled our entire hit list in a fraction of the time and material we expected.
Pre-formulation Lead
See how ORYL F1 can deliver decision-ready solubility and aggregation results for your pipeline.